Skip to main content
All lobbying filings

WILLIAMS AND JENSEN, PLLC

Lobbying for ABBVIE, INC. · Biopharmaceutical company

 Filing · LD-2 quarterly report Q3 report
Reporting period
3rd Quarter 2026
July 1 - Sep 30 · Posted Oct 20, 2026
Income
$90,000
What the client paid this registrant for the period.
Client based in
District of Columbia

Official filing document

 Lobbyists on this filing 4
  • DANIEL ZIEGLER New on this filing
    Previously held: Executive Director, Republican Study Committee; Legislative Director for Rep Doug Lamborn, Policy Director; Speaker Mike Johnson
  • JEANNE HAGGERTY New on this filing
    Previously held: Legislative Correspondent Senator Chuck Grassley and Senate Aging Committee (shared staff), Legislative Aide Senate Finance Committee, Health Policy Coordinator Health Subcommittee Energy and Commerce, Professional Staff Member
  • ROBERT BUTORA New on this filing
    Previously held: Health Policy Advisor, Senator Bill Cassidy; Senior Health Policy Advisor, Representative Leonard Lance, Health Legislative Assistant, Representative Michael Burgess
  • CHRISTOPHER E. WILCOX New on this filing
    Previously held: LA, Leg Counsel, LD & Counsel, Rep. Arcuri; LD & Counsel, Rep. Demings

A "covered position" is a government job the lobbyist held in the 20 years before registering, which the law requires them to name. See the revolving door for former members of Congress across all filings.

 Government bodies contacted 2

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

 Lobbying activity 5
Pharmacy

H.R.830/S. 864, HELP Copays Act of 2023; Pharmacy Benefit Manager transparency, including Lower Costs, More Transparency Act, monitoring efforts around direct-to-consumer policies.

Defense

Issues related to China WRT the BINSA bill.

Health Issues

340B Reform, FDA drug approvals, monitoring Food is Medicine initiatives, importation of biopharmaceutical products, pharmaceutical supply chain. Prescription drug advertising issues. Issues related to TrumpRX.

Medicare/Medicaid

Drug pricing policies, implementation of IRA drug pricing policies, access and coverage, most-favored nation drug pricing policies, ORPHAN Cures Act implementation. H.R.4299 - Protecting Patient Access to Cancer and Complex Therapies Act.

Trade (domestic/foreign)

Monitoring 232 investigations, monitoring tariffs, most favored nation drug pricing policies, pharmaceutical IP issues, issues related to China WRT the BINSA bill.

 Bills named in this filing 3
  • H.R. 830
    HELP Copays Act
  • S. 864
    HELP Copays Act
  • H.R. 4299
    Protecting Patient Access to Cancer and Complex Therapies Act

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.

Report a problem